Method for treating and diagnosing cancer by using cell-derived microvesicles
Disclosed is a method for the treatment and/or diagnosis of cancer, using bacterial cell-derived microvesicles, which is highly effective in cancer therapy with a significant reduction in side effects. Also, a method is provided for delivering of a drug therapeutic or diagnostic for a disease, using bacterial cell-derived microvesicles loaded with the drug, thereby treating and diagnosing the disease effectively and specifically.
1. A method of treating cancer in a subject in need thereof, said method comprising administering bacterial cell-derived microvesicles to said subject,
wherein the bacterial cell-derived microvesicles are derived from a Gram-positive bacteria that is genetically transformed to have a reduced toxicity; and
wherein the cancer is treated.
2. The method of claim 1 , wherein the bacteria express a substance that is therapeutic for cancer or are transformed to express the substance that is therapeutic for cancer.
3. The method of claim 1 , wherein the bacteria are transformed so that the microvesicles are mitigated in toxicity.
4. The method of claim 1 , wherein the microvesicles are loaded with a drug which mitigates the side effects of the microvesicles or a drug which enhances the anticancer activity of the microvesicles.
5. The method of claim 4 , wherein the drug which mitigates the side effects of the microvesicles is aspirin.
6. The method of claim 4 , wherein the drug enhancing anticancer activity of the microvesicles is selected from the group consisting of a drug suppressing Th17(T helper 17 cell)-mediated immune responses, a drug suppressing formation or activity of interleukin-6, a drug suppressing angiogenesis, a drug suppressing formation or activity of vascular endothelial growth factor, a drug suppressing vascular endothelial growth factor receptor-mediated signaling, a drug suppressing STAT3 (Signal transducer and activator of transcription) signaling, and an anticancer agent.
7. The method of claim 1 , wherein the genetically transformed bacteria is a LTA mutant.
8. The method of claim 1 , wherein the genetically transformed bacteria comprises a mutation in the LTA gene, wherein the mutated LTA is less immunogenic than the wild-type.